[Cortexin and metabolic activators in the therapy of post-abstinent syndrome].
Shabanov
P D
PD
Vostrikov
V V
VV
Bushkova
N V
NV
Kuzenbaeva
L B
LB
Pavlenko
V P
VP
Mokeeva
E G
EG
Tsygan
V N
VN
D000328:Adult; D000437:Alcoholism / Q000150:complications* / Q000378:metabolism / Q000523:psychology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002227:Carbazoles / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome / Q000378:metabolism / Q000517:prevention & control* / Q000523:psychology; D016896:Treatment Outcome
D001562:Benzimidazoles; D002227:Carbazoles; D004338:Drug Combinations; D036341:Intercellular Signaling Peptides and Proteins; D018696:Neuroprotective Agents; D010455:Peptides; C049825:bemethyl; C056590:cortexin; C009830:pirlindole